SCC researchers are part of Swelife financed project
SCC researchers are part of Swelife financed project regarding an epigenetic cancer therapy for an orphan cancer indication
SCC researchers are part of Swelife financed project regarding an epigenetic cancer therapy for an orphan cancer indication
SARomics Biostructures, Red Glead Discovery and researchers at Sahlgrenska Cancer Center jointly collaborate in a Swelife financed project regarding an epigenetic cancer therapy for an orphan cancer indication. This project was one of 15 financed by Swelife in order to increase health and well- being as well as increasing the sustainable growth and competitiveness of Swedish life science. In the project, a preclinical innovative epigenetic therapy will be significantly advanced towards clinical studies for an orphan cancer indication.
Read further in the press release.